Does wearing off of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

Objective The purpose of this study was to propose a definition of wearing off at the individual patient-level and determine the percentage of patients with migraine who experience wearing off of efficacy of galcanezumab at the end of a treatment cycle using this predefined threshold. Background Anecdotal reports suggest that some patients may experience wearing off of efficacy during the last week of their calcitonin gene-related peptide monoclonal antibody treatment cycle. A previous post hoc analysis of galcanezumab demonstrated consistent efficacy at each week throughout all monthly dosing intervals at the population-level, but wearing off has not been assessed at the individual patient-level. Methods Post hoc analyses of clinical trial data from four galcanezumab phase III, randomized, placebo-controlled studies in a total of 2680 patients with high-frequency episodic migraine (EVOLVE-1, EVOLVE-2, and CONQUER studies) or chronic migraine (CM; REGAIN and CONQUER studies) were conducted. Wearing off was defined as an increase of greater than or equal to 2 weekly migraine headache days in the last week of the treatment cycle compared to the second week for at least 2 months. The analyses were conducted (1) in all patients and (2) in patients with a clinically meaningful response to treatment. Results The percentage of patients meeting the threshold of wearing off was not statistically significantly different among the placebo, galcanezumab 120 mg, and galcanezumab 240 mg treatment groups, both in the total population and in patients with a clinically meaningful response (all <= 9.0%). Although the frequency of wearing off in patients with CM and prior preventive failures was numerically greater in the galcanezumab groups (8/89 or 9.0%) compared to placebo (3/95 or 3.2%), these differences were not statistically significant. Conclusions Consistent with previous analyses at the population-level that showed no evidence of decreased efficacy at the end of a treatment cycle, rates of individual patients meeting the threshold of wearing off in this analysis were low and similar among placebo, galcanezumab 120 mg, and galcanezumab 240 mg treatment groups.

Automated summary

The study aims to determine if migraine patients experience a decrease in the efficacy of galcanezumab at the end of a treatment cycle. The results showed that there were no significant differences in the percentage of patients experiencing wearing off between galcanezumab and placebo treatment groups at the individual patient-level.